- Home
- ATHA vs CLRB Comparison
ATHA vs CLRB Comparison
Compare ATHA & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- CLRB
- Stock Information
- Founded
- ATHA 2011
- CLRB 2002
- Country
- ATHA United States
- CLRB United States
- Employees
- ATHA N/A
- CLRB N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- CLRB Health Care
- Exchange
- ATHA Nasdaq
- CLRB Nasdaq
- Market Cap
- ATHA 14.8M
- CLRB 17.5M
- IPO Year
- ATHA 2020
- CLRB N/A
- Fundamental
- Price
- ATHA $3.82
- CLRB $4.82
- Analyst Decision
- ATHA
- CLRB Hold
- Analyst Count
- ATHA 0
- CLRB 2
- Target Price
- ATHA N/A
- CLRB N/A
- AVG Volume (30 Days)
- ATHA 48.3K
- CLRB 110.6K
- Earning Date
- ATHA 11-06-2025
- CLRB 11-17-2025
- Dividend Yield
- ATHA N/A
- CLRB N/A
- EPS Growth
- ATHA N/A
- CLRB N/A
- EPS
- ATHA N/A
- CLRB N/A
- Revenue
- ATHA N/A
- CLRB N/A
- Revenue This Year
- ATHA N/A
- CLRB N/A
- Revenue Next Year
- ATHA N/A
- CLRB N/A
- P/E Ratio
- ATHA N/A
- CLRB N/A
- Revenue Growth
- ATHA N/A
- CLRB N/A
- 52 Week Low
- ATHA $2.20
- CLRB $4.11
- 52 Week High
- ATHA $8.26
- CLRB $66.00
- Technical
- Relative Strength Index (RSI)
- ATHA 63.70
- CLRB 44.16
- Support Level
- ATHA $3.61
- CLRB $4.56
- Resistance Level
- ATHA $4.04
- CLRB $4.98
- Average True Range (ATR)
- ATHA 0.25
- CLRB 0.35
- MACD
- ATHA -0.16
- CLRB -0.12
- Stochastic Oscillator
- ATHA 20.92
- CLRB 13.27
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.